
TELA Bio, Inc.
93
Recent developments include the Q3 2026 earnings call reporting a net loss but revenue exceeding expectations, FDA 510(k) clearance for the fully resorbable Liora Scaffold, and appointment of Heather Getz as CEO in August 2026.
- TELA Bio reported a net loss for Q3 2026 but revenue exceeded expectations, as discussed in the Q3 2026 earnings call [N1][N2].
- The company received FDA 510(k) clearance for the fully resorbable Liora Scaffold product in October 2026 [N2].
- Heather Getz was named CEO of TELA Bio in August 2026 [N6].
- Craig-Hallum initiated coverage of TELA Bio with a Buy rating in September 2026 [N5].
TELA Bio, Inc. develops and commercializes innovative soft-tissue reconstruction solutions designed to optimize clinical outcomes by preserving and restoring the patient's own anatomy. Its flagship product lines, OviTex and OviTex PRS Reinforced Tissue Matrices, combine biologic materials derived from ovine rumen with polymer reinforcements to address unmet needs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company markets primarily in the U.S. with expanding presence in Europe and the UK, leveraging a direct sales force and partnerships with group purchasing organizations. TELA Bio holds exclusive manufacturing agreements and FDA clearances for its products and continues to invest in clinical studies and product development to enhance its portfolio and market reach [S1][S2].
TELA Bio, Inc. is a commercial-stage medical technology company specializing in soft-tissue reconstruction products, primarily the OviTex and OviTex PRS Reinforced Tissue Matrix portfolios. These products address significant market opportunities in hernia repair and plastic and reconstructive surgery, with estimated U.S. addressable markets of approximately $1.8 billion and $800 million respectively. The company holds FDA 510(k) clearances for its products and has published clinical data supporting their safety and effectiveness. As of September 30, 2026, TELA Bio reported a net loss of $9.3 million for the quarter and held $22.7 million in cash and equivalents, with a current ratio of 0.61. Recent developments include FDA clearance for the Liora Scaffold and leadership changes. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
TELA Bio's innovative product portfolio addresses large and growing markets in hernia repair and reconstructive surgery with significant unmet needs. Its proprietary technology and exclusive supply agreements provide cost advantages and barriers to entry. Clinical data and FDA clearances support product adoption, while ongoing research and development efforts aim to expand and enhance the product line. The company's expanding sales infrastructure and partnerships may increase market access and revenue potential [S1][N1][N2].
The company operates at a net loss with liquidity ratios below 1, indicating potential short-term financial constraints. Market adoption depends on continued clinical validation, regulatory approvals, and competitive dynamics in the medical device sector. Risks include reliance on a single contract manufacturer, potential reimbursement challenges, and the need to scale sales effectively. Any delays or setbacks in product development, regulatory clearance, or market acceptance could impact business performance [S2].
TELA Bio's competitive advantages include its proprietary product construction combining biologic matrices with polymer materials, exclusive manufacturing and supply agreement with Aroa securing low-cost ovine rumen material, and a broad intellectual property portfolio protecting its innovations. The company's FDA 510(k) clearances and clinical data supporting product safety and efficacy further strengthen its market position. Additionally, its direct sales infrastructure and contracts with national group purchasing organizations facilitate market penetration and customer engagement [S1].
• Financial Liquidity Risk: As of September 30, 2026, the current ratio was 0.61 and cash ratio 0.31, indicating limited short-term liquidity which may constrain operational flexibility [S2].
• Regulatory and Clinical Risk: Continued regulatory approvals and positive clinical outcomes are critical for product adoption; any adverse findings or delays could affect market acceptance [S1].
• Manufacturing Dependence: Exclusive manufacturing and supply agreement with Aroa creates dependency risk; disruptions could impact product availability [S1].
• Market Competition and Adoption: The company faces competition in hernia repair and reconstructive surgery markets; successful sales execution and reimbursement are necessary for growth [S1].
Business trends: Expansion of product portfolio with FDA clearances and clinical data supporting adoption in hernia repair and reconstructive surgery markets.
Execution milestones: Continued commercialization of OviTex and OviTex PRS products, clinical study progress, and sales infrastructure expansion.
Key risks: Financial liquidity constraints, reliance on regulatory approvals, manufacturing dependency, and competitive market dynamics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions that prioritize preservation and restoration of patient anatomy [S1].
- The company’s primary product portfolio includes OviTex Reinforced Tissue Matrix and OviTex PRS Reinforced Tissue Matrix, designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery [S1].
- OviTex products combine biologic matrices and polymer materials to address unmet needs in hernia repair and abdominal wall reconstruction, with an estimated U.S. total addressable market of approximately $1.8 billion annually [S1].
- OviTex PRS products target plastic and reconstructive surgery with an estimated U.S. addressable market opportunity of approximately $800 million annually [S1].
- The company’s products have received FDA 510(k) clearances, including recent clearances for new product configurations such as OviTex PRS Long-Term Resorbable and OviTex IHR Reinforced Tissue Matrix [S1].
- TELA Bio has conducted clinical studies such as the BRAVO study showing low hernia recurrence rates and meaningful quality of life improvements for patients using OviTex products [S1].
- The company markets primarily through a direct sales force in the U.S. with some presence in Europe and the UK, and has contracts with national group purchasing organizations to increase hospital access [S1].
- TELA Bio has an exclusive manufacturing and supply agreement with Aroa, which provides a competitive advantage through exclusive access to ovine rumen material used in its products [S1].
- The company reported revenue of $80.3 million for the year ended December 31, 2025, representing a 16% increase from the prior year, with a net loss of $38.8 million for the same period [S1].
- As of September 30, 2026, TELA Bio had cash and equivalents of $22.7 million, current assets of $44.6 million, current liabilities of $72.9 million, a current ratio of 0.61, and a cash ratio of 0.31 [S2].
- The company reported a net loss of $9.3 million and basic and diluted EPS of -$0.16 for the quarter ended September 30, 2026 [S2].
- Recent news includes Q3 2026 earnings call and report of a Q3 loss with revenue exceeding expectations, FDA 510(k) clearance for the fully resorbable Liora Scaffold, and a CEO appointment in August 2026 [N1][N2][N5][N6].
- There have been no material legal proceedings reported as of the latest quarterly filing [S2].
- Risk factors disclosed in SEC filings have not materially changed recently [S2].
Generated 2026-11-11
- N1
- N6
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-11 | www.nasdaq.com | TELA Bio (TELA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tela-bio-tela-q3-2026-earnings-call-transcript
- N2 | 2026-11-10 | www.nasdaq.com | TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/tela-bio-inc-tela-reports-q3-loss-beats-revenue-estimates
- N3 | 2026-11-04 | www.nasdaq.com | Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/arcus-biosciences-inc-rcus-reports-q3-loss-lags-revenue-estimates
- N4 | 2026-11-03 | www.nasdaq.com | Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/oculis-holding-ag-ocs-reports-q3-loss-lags-revenue-estimates
- N5 | 2026-09-26 | www.nasdaq.com | Craig-Hallum Initiates Coverage of TELA Bio at Buy | https://www.nasdaq.com/articles/craig-hallum-initiates-coverage-tela-bio-buy
- N6 | 2026-08-19 | www.nasdaq.com | TELA Bio (TELA) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tela-bio-tela-q2-2026-earnings-call-transcript
- N7 | 2026-08-10 | www.nasdaq.com | TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/tela-bio-inc-tela-reports-q2-loss-lags-revenue-estimates
- N8 | 2026-08-06 | www.nasdaq.com | Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/puma-biotech-pbyi-q2-earnings-and-revenues-top-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


